Although copy number variants (CNVs) are important in genomic medicine, CNVs have not been systematically assessed for many complex traits. Several large rare CNVs increase risk for schizophrenia (SCZ) and autism and often demonstrate pleiotropic effects; however, their frequencies in the general population and other complex traits are unknown. Genotyping large numbers of samples is essential for progress. Large cohorts from many different diseases are being genotyped using exome-focused arrays designed to detect uncommon or rare protein-altering sequence variation. Although these arrays were not designed for CNV detection, the hybridization intensity data generated in each experiment could, in principle, be used for gene-focused CNV analysis. Our goal was to evaluate the extent to which CNVs can be detected using data from one particular exome array (the Illumina Human Exome Bead Chip). We genotyped 9100 Swedish subjects (3962 cases with SCZ and 5138 controls) using both standard genome-wide association study (GWAS) and exome arrays. In comparison with CNVs detected using GWAS arrays, we observed high sensitivity and specificity for detecting genic CNVs X400 kb including known pathogenic CNVs along with replicating the literature finding that cases with SCZ had greater enrichment for genic CNVs. Our data confirm the association of SCZ with 16p11.2 duplications and 22q11.2 deletions, and suggest a novel association with deletions at 11q12.2. Our results suggest the utility of exome-focused arrays in surveying large genic CNVs in very large samples; and thereby open the door for new opportunities such as conducting well-powered CNV assessment and comparisons between different diseases. The use of a single platform also minimizes potential confounding factors that could impact accurate detection.
INTRODUCTION
The assessment of structural variation, particularly copy number variation, has led to important insights into the causes of many genomic disorders. 1 CNVs are known to play a role in the etiology of many complex traits, particularly neuropsychiatric disorders like schizophrenia (SCZ), autism and developmental delay. [2] [3] [4] [5] Indeed, CNV evaluation has become a routine diagnostic test in medical genetics, including the evaluation of childhood-onset neurobehavioral disorders.
Although CNVs are of clear importance in genomic medicine, our knowledge base has important deficiencies. For most rare CNVs, large numbers of samples have not been assessed to establish population frequencies and thereby enabling precise effect size estimation. The impact of many CNVs is pleiotropic; quantifying their phenotypic impact requires evaluation of multiple large case groups. For example, deletion or duplication of 16p11.2 was initially associated with autism, 6 and subsequent studies expanded the phenotype to include mental retardation, epilepsy, developmental delay, SCZ and alterations in brain and body size. 2, [7] [8] [9] In some instances, large samples were evaluated with different technologies resulting in uncertainty in combining results. Most importantly, CNVs have not been systematically assessed for many complex traits, and their role is unknown for many biomedical diseases.
As many CNVs important in genomic medicine are uncommon or rare, genotyping large numbers of subjects is essential. Exomefocused single-nucleotide polymorphism (SNP) arrays ('exome chips') are being used to analyze the genomes of more than one million research subjects to type the protein-altering sequence variation that is segregating at low allele frequencies. Although such arrays were designed to interrogate sequence variation, they could in principle also be used as a gene-centric CNV array. If so, then this would enable CNV studies in large sample sizes along with well-powered comparisons between different diseases. Importantly, it would also take advantage of a moment in time at which many large cohorts are being scanned on a common platform within a relatively short time window thereby minimizing the platform and batch variation that can complicate CNV metaanalysis. Thus, the goal of this report was to evaluate the capacity of the Illumina Human Exome BeadChips to detect CNVs.
SUBJECTS AND METHODS Subjects
The parent study 10 is described in detail in Supplementary Methods. All procedures were approved by ethical committees at the Karolinska Institutet in Sweden and at the University of North Carolina at Chapel Hill in the United States, and all subjects provided written informed consent (or legal guardian consent and subject assent). Cases with SCZ (N ¼ 5351) were identified via the Swedish Hospital Discharge Register, which captures all public and private inpatient hospitalizations. The validity of the case definition of SCZ is strongly supported. Controls (N ¼ 6509) were selected at random from Swedish population registers. DNA was extracted from all 11 850 Swedish subjects from peripheral blood samples using Qiagen Technologies at the Karolinska Institutet Biobank.
Exome array genotyping DNA samples were sent to the Broad Institute Genetic Analysis Platform for genotyping, and are placed on 96-well plates for processing using the Illumina Infinium HumanExome BeadChip v1.0 (Illumina Inc., San Diego, CA, USA). Majority of Exome genotypes were called using GenomeStudio v2010.3 (Illumina Inc.) with the calling algorithm/genotyping module version 1.8.4 using the custom cluster file StanCtrExChp_CEPH.egt, subsequent processing of genotype calling was done by zCall. 11 The Broad Institute did not filter any SNP based off of technical quality control metrics. Only samples passing an overall call rate of 98% criteria and standard identity check were released.
Genome-wide association study array genotyping DNA samples were genotyped in six batches (Sw1-6) at the Broad Institute using Affymetrix 5.0 (Affymetrix Inc., Santa Clara, CA, USA; 3.9%), Affymetrix 6.0 (Affymetrix Inc.; 38.6%) and Illumina OmniExpress (Illumina Inc.; 57.4%) arrays according to the manufacturers' protocols (Supplementary Table 1) . Genotype calling and quality control were done in four sets corresponding to data from Affymetrix 5.0 (Sw1), Affymetrix 6.0 (Sw2-4) and the OmniExpress batches (Sw5 and Sw6). Genotypes were called using Birdsuite (Affymetrix) or BeadStudio (Illumina). SNP-based quality control filters (subject quality control (QC) I) were applied to exclude subjects using the following criteria: SNP missingness X0.05 (before sample removal); subject missingness X0.02; autosomal heterozygosity deviation; and a randomly selected member of any pair of subjects with high relatedness. The relatedness testing was done with PLINK 12 using 39 239 suitable SNPs (Supplementary Methods), and high relatedness was defined using p40.2. After quality control, a total of 11 224 subjects (5001 cases with SCZ and 6243 controls) remained and were used for subsequent CNV calling and analysis.
CNV calling
All genomic locations are given in NCBI build 37/UCSC hg19 coordinates. To detect CNVs from Illumina exome arrays, we applied PennCNV (June 2011 version) 13 with customized parameters. PennCNV is a robust method designed for Illumina arrays, 14 and used here to facilitate use of our pipeline by other investigators. A step-by-step instruction on how to use PennCNV for exome arrays along with parameters used in this study are provided in Supplementary Methods. Key information on preparation of input parameters is summarized below. PennCNV applies a hidden Markov model (HMM) to segment the normalized and transformed probe intensities (that is, log R ratios (LRRs) and B allele frequencies) and incorporates SNP allele frequencies (that is, population frequency of the B allele (PFB)). Our general approach to identify customized PennCNV parameters is based on HMM theory and computational experiments designed for optimization. For baseline HMM transition probabilities for probes within 5 kb, we used parameters designed for Illumina GWAS arrays. To account for the skewed distribution of exome array probes, the transition probabilities were set to depend on inter-probe distance (that is, transitioning to a different copy number state is penalized less when probes are farther apart). For HMM emission probabilities, the initial values were estimated empirically from 12 known large CNVs, through manual examination of corresponding probe intensities on exome arrays (Supplementary Figure 3 ) and simple linear interpolation. 13 For optimization of emission probabilities, we tested a series of parameter values using a large set of training samples independent of the final subjects used in this study.
The PFB values for all SNPs are compiled from a large number of control individuals using the 'compile_pfb.pl' script in PennCNV. 13 SNP with a PFB value of 0 is treated as non-polymorphic markers by setting its PFB to 2.
To detect CNVs from genome-wide association study (GWAS) arrays, we applied two established methods, the Birdseye tool in Birdsuite 15 and PennCNV (June 2011 version). 13 Birdseye was initially developed for Affymetrix platform and was then extended to handle Illumina GWAS arrays. 14, 16 PennCNV was initially developed for Illumina platform and was then extended to handle Affymetrix GWAS arrays. 14, 16 Birdseye uses an HMM to normalized probe intensities for each allele, using model priors (that is, allele-specific probe responses) generated separately for each type of GWAS arrays. PennCNV applies an HMM to LRR and B allele frequency, using default program parameters recommended for each type of GWAS arrays. Additional computational details such as input file preparation can be found in Supplementary Methods.
CNV quality control
Quality control steps for initial CNV callsets are described in detail in Supplementary Methods, and were used to remove low confidence CNVs or CNVs overlapping large genomic gaps. Additional subject quality control (subject QC II) was conducted to exclude subjects with high probe intensity variance or excessive CNVs (495th percentiles). As the CNV detection algorithms (PennCNV and Birdseye) were optimized to identify rare CNVs, we extracted autosomal CNVs present in o0.01 of all post-QC subjects.
In silico sex-mixing experiments for exome array For initial evaluation of our CNV calling protocol for exome array, we simulated heterozygous deletions using a sex-mixing approach. 15 After excluding the pseudo-autosomal regions (to remove natural CNV), we used a total of 5041 chromosome X probes from the exome array. Among the 9100 Swedish samples that passed QC, we selected samples with a standard deviation of LRR o0.35 for the chrX probe intensities to form the simulation pool. To estimate specificity, we created 1000 simulated independent samples of normal copy number. In each simulation, a female sample was randomly chosen and its intensities of all chrX probes were randomly permuted to create a 'CNV-free' chromosome. After applying the CNV calling protocol, any CNV detected from such chromosome was regarded as 'false positive'. To estimate sensitivity, we created 1000 simulated independent samples, where each contains heterozygous deletions spanning variable numbers of (N) consecutive probes at known locations. Each simulation was generated as following: (1) randomly choose a female sample; (2) randomly choose a male sample; (3) randomly permute intensities of all chrX probes to create a 'CNV-free' chromosome; and (4) replace consecutive N probes from the female sample with the intensities of the corresponding probes from a male sample to create a virtual sample with pseudo-deletions at known locations. After applying the CNV calling protocol, sensitivity was computed by the proportion of 'true positive' deletions of all predicted deletions.
Analyses of human CNV data
Autosomal CNVs were used for all analyses. Large CNVs with previously reported associations with SCZ were specifically examined. 16, 18 To explore novel loci from exome arrays, we scanned the genome with single-marker analysis as implemented in PLINK. 12 The single-marker analysis examined the breakpoints of all events with X70 kb in length (approximation to a size threshold of X100 kb commonly used for GWAS data set 16 ), for duplications and deletions separately and combined. Association tests (both region and single marker) were one-sided with point-wise and multiple-testing adjusted empirical P-values computed using 10 000 permutations of case-control status. Genic CNVs were extracted as CNVs intersect any genes, where the gene model is the maximal transcripts for RefSeq mRNA genes resulting in a total of 23 101 genes. Burden tests were performed using genic CNVs using PLINK 12 for duplications and deletions separately and combined, and for a range of CNV size classes. The rate of genic CNVs was reported by PLINK, 12 based on which fold change was computed as case-control ratio of genic CNV rate and indicates increased risk in disease per CNV rate. Figure 1 summarizes our experimental workflow and CNV data sets. After quality control, there were 3962 cases with SCZ and 5138 controls genotyped using exome and GWAS arrays (Affymetrix 5.0 (3.4%), Affymetrix 6.0 (33.3%) and Illumina OmniExpress (63.3%)) (Supplementary Table 2 ). The 250K SNPs on Illumina Human Exome BeadChips were derived from exome sequencing of 12 028 European subjects (including B500 subjects from this study), and met the following criteria: exonic or splice site variant of predicted functionality, minor allele observed a total of X3 times, minor allele observed in X2 different cohorts, passed sequencing quality control and high Illumina SNP design scores (http://genome.sph.umich.edu/wiki/Exome_Chip_Design).
RESULTS

Human CNV data
We considered CNV calls from genome-wide SNP arrays (that is, GWAS arrays) as a best-practice reference data set to which we compare CNV calls from exome arrays. CNVs from genome-wide SNP arrays are arguably the most prevalent and impactful source of CNV data to date. CNVs estimated from GWAS data generally have high sensitivity and specificity for large CNVs with substantial probe coverage.
14 Three types of GWAS genotyping platforms were used. CNV calls may differ depend on the analytic tools employed.
14 If not accounted for, then these factors could confound the comparison of exome array CNVs with GWAS array CNVs. Therefore, to control for platform difference, we conducted the comparison using all subjects and using subsets of subjects stratified by GWAS array type. To control for analytic difference, we employed two established methods, Birdseye and PennCNV, for GWAS arrays.
Coverage
We evaluated the coverage of the exome and GWAS arrays across the genome, in genes and in regions of interest. As expected, the exome array has inferior genome-wide coverage although its genic probe density is considerable (Supplementary Table 3 ; Figure 2 ; Supplementary Figure 2) . With 96% genic probes, the exome array includes at least one SNP in 79% of all genes, comparable to GWAS arrays (81% Affymetrix 6.0 and 82% Illumina OmniExpress). Among the 79% genes, the number of probes per gene ranges 1-849 (median 9 probes) with a mean genic probedensity of 3.9 probes/20 kb.
The ability to call a CNV using the exome array depends on size and number of probes, and CNVs X400 kb with a mean of X1 exome probe/20 kb should be detectable (Figure 4) . We evaluated exome array coverage in regions of known importance (Supplementary Table 4): 4,5 33/37 autism regions are X400 kb (median 338 exome probes); 81/86 developmental delay regions are X400 kb (median 268 exome probes); 21/21 CNVs important for psychiatric disorders are X400 kb (median 186 exome probes); and 38/42 DECIPHER CNVs are X400 kb (median 175 exome probes). Thus, in concept, the exome array should allow detection of many large CNVs of importance in genomic medicine.
Initial evaluation of exome array CNVs Sensitivity and specificity were estimated based on 1000 simulations via in silico sex-mixing experiments. Full results are displayed in Supplementary Table 5 . In summary, sensitivity was 0.998 for deletions including X10 exome array probes. As expected, sensitivity was less for CNVs with poor probe coverage (o1probe/ 20 kb) or from noisier arrays (for example, standard deviation of LRR 40.35). Specificity was 0.997 for CNVs with confidence scores X10. These in silico simulation results suggested appropriate quality control thresholds that were implemented in subsequent analyses.
Exome versus GWAS arrays
We created stringent CNV callsets on the same subjects using exome array (using PennCNV) and GWAS genotyping (using Birdseye and PennCNV). The CNV callsets are compared in Supplementary Table 6 ; Supplementary Figures 4 and 5 . CNVs predicted from exome arrays are smaller than those from GWAS arrays. The total length of CNVs per subject from the exome array was B60% of that of from genic GWAS CNVs. This result was expected based on our analyses of exome array coverage (see Figure 3 and Supplementary Figure 3 for CNV examples). Although both GWAS and exome array CNVs detected more duplications than deletions, the relative proportion of duplications was even greater from the exome array. This could result from technical differences (for example, in probe design, CNV calling algorithms or quality control), but it is possible that genic duplications reduce fitness less than genic deletions. As shown in Supplementary   Figure 1 . Experimental workflow and copy number variant (CNV) data sets. Table 6 , the relative proportion of duplications was more comparable after controlling for difference in probe design. In Supplementary Figure 5 , we compared CNV size distribution for exome and GWAS arrays stratified by genotyping batch (Sw1 through Sw6), array type (Affymetrix 5.0, Affymetrix 6.0 and Illumina OmniExpress) and CNV calling method (Birdseye and PennCNV). For genome-wide CNVs, GWAS array data sets showed notable variability between batches, which was primarily due to difference in array type and secondarily due to difference in calling method. After restricting to genic CNVs, GWAS array data sets were more comparable across strata. In contrast, exome array data set showed consistency across strata.
We contrasted GWAS to exome array CNVs. As discussed above, we considered GWAS array CNVs as the best-practice reference for estimating sensitivity and specificity (computational details described in Supplementary Methods and Supplementary  Figure 1 ). We estimated sensitivity by computing the proportion of GWAS CNVs captured by the exome array and specificity by the proportion of exome array CNVs overlapping with any GWAS CNV. We did for all CNVs and after stratifying by size and deletion/ duplication type. First, we conducted full-sample analysis using 9100 subjects that passed all QC steps and had both GWAS and exome array CNV calls. We then stratified the CNV data for 307 (3.4%) subjects genotyped using Affymetrix 5.0; 3030 (33.3%) using Affymetrix 6.0; and 5736 (63.3%) subjects using Illumina OmniExpress. In sum, a total of eight comparisons (listed in Supplementary Table 7) were conducted to control for differences in array type and CNV calling method. Figure 4 displays representative results based on the full sample and comparing exome array CNVs with GWAS CNVs produced by Birdseye. Figure 4a shows the relatively poor sensitivity of the exome array for detecting GWAS CNVs genome-wide, a result anticipated from probe coverage. However, as expected, detection of genic CNVs is more sensitive. About 60% of GWAS CNVs intersect at least one gene and, of these, 46% had good exome probe coverage (that is, X1 probe/20 kb). Figures 4c and d compare genic CNVs between GWAS and exome arrays, and shows considerably higher sensitivity and higher specificity in comparison with the corresponding genome-wide estimates. For genic CNVs X400 kb with good probe coverage, the sensitivity to detect deletions was B0.95 and specificity 0.68; for duplications, sensitivity and specificity were B0.8. For genic CNVs X900 kb, sensitivity and specificity for deletions and duplications were 0.90-0.95. To evaluate the impact of the CNV frequency filter (that is, selecting CNVs present in o0.01 of all subjects), we repeated the analysis by filtering in one data set and comparing with all calls in the second data set and observed identical result for CNVs X400 kb and 1% increase in sensitivity and specificity for CNVs o400 kb. Supplementary Table 7 summarizes sensitivity and specificity estimated for genic CNVs X400 kb from all eight comparisons. Supplementary Figures 6-9 display sensitivity and specificity estimated for all CNV sizes using combinations of two subsamples (Sw2-4 genotyped on Affymetrix 6.0 or Sw5-6 genotyped on Illumina OmniExpress) and two calling methods for GWAS arrays (Birdseye or PennCNV). Sw1 was excluded because of its insufficient sample size (N ¼ 307, 3.4%). Between types of GWAS arrays, we observed B3-5% variability in sensitivity estimates and B3-14% variability in specificity estimates. Between CNV calling methods within array type, we observed 2-4% variability in sensitivity estimates and 1-7% variability in specificity estimates. The best estimates were obtained using GWAS CNVs derived from Sw5-6 (Illumina) and PennCNV, where both platform and calling Figure 4 . Summary results for comparing copy number variant (CNV) calls between exome and genome-wide association study (GWAS) arrays. GWAS array CNVs were used as the reference for all comparisons. Comparisons were stratified by CNV type (all CNVs in black, deletions in red and duplications in blue) and by size (x axis). Sensitivity and specificity: (a) Sensitivity to detect any GWAS CNVs. (b) Specificity of the exome array CNV data set to detect any GWAS CNV, estimated by computing the proportion of exome array CNVs overlapping any GWAS CNVs for each size bin of the exome array CNVs. (c) Sensitivity to detect GWAS CNVs limited to genic CNVs and accounting for probe coverage (intersect X1 gene and X1 exome array probe/20 kb of its length). (d) Specificity of the exome array CNV data set compared with genic CNVs from GWAS arrays. Burden tests: The y axis shows fold changes for CNV burden of cases versus controls, and the x axes indicate CNV size bins (total numbers of CNVs per bin in parentheses). (e) Burden test using genic CNVs from the GWAS data set. (f ) Burden test using genic CNVs from the exome array data set. Note that the x axes stop at the particular bin when the total numbers of CNVs per bin (in parentheses) are comparable between (e) and (f ) and hence the total number of bins displayed in (e) and (f ) are different.
method were matched most closely between the exome array and the GWAS reference. In summary, the capability of exome array for CNV calling is robust. It detects large genic CNVs with at least B80% sensitivity and specificity for CNVs X400 kb and B90% sensitivity and specificity for CNVs X900 kb.
Exome array versus exome sequencing CNVs Fromer et al 17 recently developed XHMM, a method to call CNVs from exome sequencing read-depth data. As XHMM was developed using sequencing from B1000 Swedish subjects on whom we also had exome array CNV calls, we repeated our analyses to compare CNVs from exome arrays to exome sequencing. We observed high agreement for genic CNVs X300 kb (B81% sensitivity and B71% specificity).
Known CNVs Several large CNVs increase risk for SCZ, 5 and are known to be present in these samples. 16, 18 We therefore studied the ability of exome array to detect these CNVs (Table 1) . Exome array CNVs had very high agreement with GWAS CNVs as 35/36 were correctly identified. One 16p11.2 duplication was missed due to samplespecific noise as measured in probe-intensity variance, and the post facto use of more liberal emission parameters rescued this CNV while compromising the specificity. Given its reliability, exome array CNVs were used to perform regional association tests with statistical significance established empirically. Two loci were significantly enriched in SCZ subjects: duplications at the 16p11.2 locus (9 cases, 1 control; P ¼ 0.0033, multiple-testing adjusted P ¼ 0.0033) and deletions at the 22p11.2 locus (7 cases, 1 control with partial deletion; P ¼ 0.015, multiple-testing adjusted P ¼ 0.034).
Novel loci A novel nominal association was detected using the exome arrays at 11q12.2 (P ¼ 0.0069, multiple-testing adjusted P ¼ 0.18). Six deletions in cases with SCZ were detected with the smallest common region spanning chr11:60531180-60620982 (Supplementary Table 8 ). All six deletions were also detected by GWAS arrays with the smallest common region spanning chr11: 60547604-60624496 (Supplementary Table 8 ). Probe intensities are displayed in Supplementary Figures 11 and 12 , confirming the accuracy of these deletions. No deletion was detected in controls.
Burden tests Several studies reported a greater burden of rare CNVs in SCZ cases versus controls, particularly for genic CNVs. 16, 19, 20 Burden tests were performed with respect to type and size of the genic CNVs. Figure 4e depicts the results for GWAS CNVs that were based on 9100 subjects and the Birdseye algorithm: for genic CNVs X100 kb, cases with SCZ had 1.12 Â more CNVs than controls (1.13 Â for deletions and 1.11 Â for duplications). As in our prior report, 16 deletions and duplications had somewhat different profiles: the association of deletion burden increased more noticeably with respect to CNV size while duplications showed a more gradual increase. Figure 4f shows burden results for exome array CNVs. Overall, these results also showed greater CNV burden in cases compared with controls, particularly for larger deletions. Intriguingly, the fold change estimates for the exome array CNVs were larger than for GWAS arrays (for example, for exome array CNVs X400 kb, cases had 1.53 Â increased burden overall, 2.22 Â higher for deletions and 1.36 Â higher rate for duplications). The burden estimates for GWAS CNVs X400 kb were considerably lower and did not reach similar fold change values until X900 kb (1.54 Â , 2.19 Â and 1.31 Â overall, deletions and duplications). Similar analyses were obtained using subsamples and different calling methods for GWAS arrays (Supplementary Figures 6(e, f)-9(e, f) ).
The higher fold change of genic CNV rate observed from exome arrays can be attributed to several technical reasons. The primary reason was that relatively uniform sample processing reduced experimental variability. Supplementary Figure 10 compares the distribution of the standard deviation of normalized and transformed probe intensities (that is, LRR_SD) between GWAS and exome arrays. LRR_SD was used as a surrogate measure of experimental noise. GWAS arrays showed experimental variability between genotyping batches and platforms. In contrast, exome arrays showed consistency for the entire cohort, as all samples were scanned on a common platform in the same facility within a short time window. Additional explanation is probe design differences between types of GWAS arrays and between GWAS and exome arrays. We conducted burden tests using the rate of genic CNVs and adjusted for the shorter CNV length from exome arrays. These strategies accounted for most difference in probe design between GWAS and exome arrays but residual effect remains.
DISCUSSION
In a large Swedish SCZ case/control sample, we demonstrated that the Illumina Human Exome BeadChip can be used to detect large genic CNVs with B80% sensitivity and specificity for CNVs X400 kb and B90% sensitivity and specificity for CNVs X900 kb. CNVs known to be important to SCZ were genotyped with high accuracy. The data strongly confirm the association of SCZ with 16p11.2 duplications and 22q11.2 deletions. A greater burden of genic CNVs in SCZ cases was detected, and the exome array yielded higher burden estimates and greater significance levels than GWAS arrays.
The relative homogeneity of this Swedish sample is one of its main strengths. The quality of a CNV callset depends on multiple factors, including coverage, resolution, the realized signal to noise ratios, and the performance of the detection algorithms.
14, 16 Our comparative results are robust and generalizable given the use of two different CNV calling algorithms and two mainstay GWAS genotyping platforms. Other computational methods should be explored for CNVs detection from the exome array, and the use of multiple computational methods may be beneficial. 14, 16 An important consideration is that many exome array SNPs are monomorphic, and allelic ratios or relative intensities do not contribute to CNV detection. Thus, the power to detect CNVs mainly depends on the total intensities, and primarily reflects CNV size.
We suggest that future work should evaluate smaller exome array CNVs carefully as some proportion might be true CNVs potentially important to SCZ but undetected using GWAS arrays. The smallest CNVs (7.8% o1 kb, 19% 1-5 kb and 11% 5-10 kb) often span a large number of exome array probes. On the basis of our simulation study, some small deletions spanning X10 probes might be real but missed by the GWAS. However, some of these small CNVs might result from aberrant probe intensities due to technical bias such as rare alleles on the exome array. These results could be combined with high-throughput sequencing data to identify CNVs and to establish precise CNV boundaries.
A novel nominally associated 90 kb deletions were observed at 11q12.2 using exome arrays. This result was based on an exploratory analysis using 9100 subjects that had both exome and GWAS array data. Comprehensive CNV-disease association analyses using this Swedish sample are reported elsewhere.
In conclusion, our results suggest the utility of exome-focused arrays in surveying large genic CNVs in very large samples. Many large cohorts for psychiatric and non-psychiatric diseases are being scanned on this common platform. The widespread use of exome arrays suggests new opportunities such as conducting well-powered CNV assessment and comparisons between different diseases. Such cross-disorder CNV meta-analysis will facilitate our understanding of the contributions of large genic CNVs to psychiatric diseases by establishing precise estimates of their effect size and quantifying their phenotypic impact. The use of a single platform minimizes potential confounding factors that could impact accurate detection.
